We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Charles River Strengthens Grasp of Cell and Gene Therapy With Cognate Purchase
Charles River Strengthens Grasp of Cell and Gene Therapy With Cognate Purchase
In the latest in a series of recent moves that greatly expand its presence in cell and gene therapies, Charles River Laboratories is acquiring Cognate BioServices, a Baltimore, Md.-based cell and gene therapy contract development and manufacturing firm for $875 million.